Cost Effectiveness of Influenza Vaccination in Older Adults
Several recent studies have assessed the benefits of extending influenza vaccination programmes, which are currently targeted primarily at those aged over 65 years, to those aged 50–64 years. We identified and reviewed all costeffectiveness studies of influenza vaccination in those aged 50–64 years published before July 2008. While the studies suggest that vaccination in this age-group is likely to be cost effective, these results were dependent on several key assumptions. The estimates of serious outcomes due to influenza and the estimates of vaccine effectiveness (VE) against these outcomes were found to have the most influence on cost effectiveness. However, due to factors including mismatches between the measure of VE and the outcome under consideration, as well as various other data limitations, there is significant uncertainty around these key assumptions that was not well explored. There was a failure in some studies to report fundamental inputs such as discount rates. Overall, there was a general lack of transparency in the studies and, consequently, the conclusions around the cost effectiveness of influenza vaccine in those aged 50–64 years must be interpreted with caution.
KeywordsInfluenza Influenza Vaccine Influenza Vaccination Vaccine Effectiveness Utility Weight
Anthony Newell has received research grants for investigator-driven research from GlaxoSmithKline Australia. Heath Kelly has received grants and consultancy funds from companies that manufacture influenza vaccines. Stuart Harsley is an employee of CSL Limited and owns shares in the company. Paul Scuffham has no conflicts of interest to declare.
- 10.Drummond M, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005Google Scholar
- 12.Australian Institute of Health and Welfare. 2004 adult vaccination survey: summary results. Canberra: AIHW & DoHA, 2005. Report no.: PHE 56Google Scholar
- 22.Lopez L, Huang QS. Influenza in New Zealand 2008. Porirua: Institute of Environmental Science and Research (ESR); 2009 [online]. Available from URL: http://www.surv.esr.cri.nz/virology/influenza_annual_report.php [Accessed 2009 Jun 15]
- 26.Demicheli V, Rivetti D, Deeks JJ, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2004; (3): CD00126Google Scholar
- 27.Demicheli V, Rivetti D, Deeks JJ, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2001; (4): CD001269Google Scholar
- 30.Jefferson TO, Rivetti D, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2007; (2): CD001269Google Scholar
- 34.Maciosek MV, Coffield AB, Edwards NM, et al. Methods for prioritizing clinical preventive services: technical report prepared for the National Commission on Prevention Priorities. Minneapolis (MN): HealthPartners Research Foundation, 2006.Google Scholar
- 35.Prior G. Self-reported health: health survey for England ‘96. London: The Stationery Office, 1998Google Scholar
- 38.Grosse SD. Prevention effectiveness: a guide to decision analysis and economic evaluation [appendix I: productivity loss tables]. 2nd ed. New York: Oxford University Press, 2003Google Scholar